|
May 8
|
Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates
|
|
May 8
|
Editas Medicine Announces First Quarter 2024 Results and Business Updates
|
|
May 5
|
Editas Medicine, Inc. (NASDAQ:EDIT) is a favorite amongst institutional investors who own 71%
|
|
May 2
|
Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
|
|
May 1
|
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
|
|
Apr 29
|
12 Under-the-Radar Stocks With Massive Upside for 2024
|
|
Apr 26
|
Will Editas Medicine (EDIT) Report Negative Q1 Earnings? What You Should Know
|
|
Apr 22
|
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
|
|
Mar 29
|
Why Is Editas (EDIT) Down 26.2% Since Last Earnings Report?
|
|
Mar 7
|
1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right.
|
|
Mar 6
|
Insider Sells Shares of Editas Medicine Inc (EDIT)
|
|
Mar 4
|
1 Beaten-Down Stock With 55% Upside, According to Wall Street
|
|
Feb 10
|
Top 11 CRISPR Stocks To Invest In
|
|
Feb 6
|
What Makes Editas (EDIT) a New Buy Stock
|
|
Jan 31
|
Editas Medicine to Participate in Upcoming Investor Conferences
|
|
Jan 28
|
2 Under-the-Radar Stocks With Incredible Upside Potential
|
|
Jan 25
|
Editas Medicine (NASDAQ:EDIT) shareholders have endured a 87% loss from investing in the stock three years ago
|
|
Jan 15
|
Down 88%, Could Editas Medicine Be a Good Investment Now?
|
|
Dec 23
|
Editas Just Caught a Break Thanks to Vertex Pharmaceuticals
|
|
Dec 10
|
12 Best Genomics Stocks To Buy Now
|